US5108759A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Endothelial envelopment drug carriers
Assignee: Abeona Therapeutics Inc
•
Filing: 1989-12-08
•
Granted: 1992-04-28
•
Expires: 2009-12-08
Abstract
Abstract This application describes the preparation and in vivo testing of surface coatings and matrix materials, which when applied to or caused to comprise the carriers for drugs and diagnostic agents, and administered in a fashion that allows efficient vascular access, causes the carriers to recognize determinants present or normal or focally diseased endothelium, and induces the following in vivo effects: 1) rapid, partial or total endothelial envelopment of the drug (diagnostic) carrier; 2) sequestration of the carrier and protecting entrapped agent from blood vascular clearance at an early time (2 minutes) when the endothelial pocket which envelops the carrier still invaginates into the vascular compartment; 3) acceleration of the carrier's transport across or through the vascular endothelium and/or subendothelial structures into the tissue compartment (interstitium); and 4) improvement of the efficiency with which the drug (or diagnostic) carrier migrates across the endothelium, or epi-endothelial or subendothelial barriers, such that a lower total drug dose is required to obtain the desired effect relative to that required for standard agents.
Inventors
- 👤 David F. Ranney
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:41
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/51; A61K9/5107; A61K9/513; A61K9/5146; A61K47/00; A61K47/50; A61K47/51; A61K47/56; A61K47/61; A61K47/69; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1652; A61K9/167; A61K9/5005; A61K9/5021; A61K9/5036; A61K9/5161; Y; Y10; Y10S; Y10S436/00; Y10S436/829; Y10T; Y10T428/00; Y10T428/29; Y10T428/2982; Y10T428/2984; Y10T428/2989
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
112 words
A composition comprising a multivalent binding agent surface which binds determinants of endothelial or epithelial cells; wherein the composition is a microsphere, microaggregate, or macromolecule less than about 250 micrometers in size, and has a matrix capable of containing a drug or diagnostic agent at a content of at least 12% (w/w); and wherein the multivalent binding agent surface consists of carbohydrate, oligosaccharide, monosaccharide, negatively charged polysaccharide, negatively charged oligosaccharide, dextran sulfate, glycosaminoglycan, heparin, heparin fragment, synthetic heparin analogue, heparan sulfate, dermatan sulfate, chondroitin sulfate, hyaluronic acid; and which induces rapid partial or total envelopment of said composition by endothelial or epithelial cells and facilitated migration across said cells into proximal tissues.
Claim 2
Dependent Claim
112 words
A composition comprising a multivalent binding agent surface which binds determinants of endothelial or epithelial cells; wherein the composition is a microsphere, microaggregate, or macromolecule less than about 250 micrometers in size, and has a matrix capable of containing a drug or diagnostic agent at a content of at least 12% (w/w); and wherein the multivalent binding agent surface consists of carbohydrate, oligosaccharide, monosaccharide, negatively charged polysaccharide, negatively charged oligosaccharide, dextran sulfate, glycosaminoglycan, heparin, heparin fragment, synthetic heparin analogue, heparan sulfate, dermatan sulfate, chondroitin sulfate, hyaluronic acid; and which induces rapid partial or total envelopment of said composition by endothelial or epithelial cells and facilitated migration across said cells into proximal tissues.
Claim 3
Dependent Claim
92 words
A composition comprising a multivalent binding agent surface which binds determinants of endothelial or epithelial cells; wherein the composition is a microsphere, microaggregate, or macromolecule less than about 250 micrometers in size, and has a matrix capable of containing a drug or diagnostic agent at a content of at least 12% (w/w); and wherein the multivalent binding agent is a heparin, a heparin fragment, or synthetic heparin analogue, which induces rapid partial or total envelopment of said composition by endothelial or epithelial cells and facilitated migration across said cells into proximal tissues.
Claim 4
Dependent Claim
92 words
A composition comprising a multivalent binding agent surface which binds determinants of endothelial or epithelial cells; wherein the composition is a microsphere, microaggregate, or macromolecule less than about 250 micrometers in size, and has a matrix capable of containing a drug or diagnostic agent at a content of at least 12% (w/w); and wherein the multivalent binding agent is a heparin, a heparin fragment, or synthetic heparin analogue, which induces rapid partial or total envelopment of said composition by endothelial or epithelial cells and facilitated migration across said cells into proximal tissues.
Claim 5
Dependent Claim
102 words
A composition comprising a multivalent binding agent surface which binds determinants of endothelial or epithelial cells; wherein the composition is a microsphere, microaggregate, or macromolecule less than about 250 micrometers in size, and has a matrix capable of containing a drug or diagnostic agent at a content of at least 12% (w/w); and wherein the multivalent binding agent consists essentially of heparin, heparin fragment, synthetic heparin analogue, heparan sulfate, dermatan sulfate, chondroitin sulfate, hyaluronic acid or dextran sulfate, which induces rapid partial or total envelopment of said composition by endothelial or epithelial cells and facilitated migration across said cells into proximal tissues.
Claim 6
Dependent Claim
102 words
A composition comprising a multivalent binding agent surface which binds determinants of endothelial or epithelial cells; wherein the composition is a microsphere, microaggregate, or macromolecule less than about 250 micrometers in size, and has a matrix capable of containing a drug or diagnostic agent at a content of at least 12% (w/w); and wherein the multivalent binding agent consists essentially of heparin, heparin fragment, synthetic heparin analogue, heparan sulfate, dermatan sulfate, chondroitin sulfate, hyaluronic acid or dextran sulfate, which induces rapid partial or total envelopment of said composition by endothelial or epithelial cells and facilitated migration across said cells into proximal tissues.
Claim 7
Dependent Claim
35 words
The composition of claim 1 defined further as consisting of microparticles or microaggregates coated with heparins which bind to complementary substances present on endothelium or epithelium, said complementary substances including heparan sulfates and antithrombin III.
Claim 8
Dependent Claim
65 words
The composition of claim 1 wherein the multivalent binding agent surface coating is reversibly blocked by a chemical moiety that renders the multivalent binding agent initially covert and wherein the reversibly blocking chemical moiety is susceptible to release by triggering agents including lowered pH, altered temperature, contact with normal or abnormal endothelia or epithelia, altered enzyme levels, degradative enzymes, radiofrequency energy, ultrasound, magnetism or electricity.
Claim 9
Dependent Claim
17 words
The composition of claim 1 wherein the drug or diagnostic agent is a drug active against microorganisms.
Claim 10
Dependent Claim
15 words
The composition of claim 6 wherein the drug or diagnostic agent is an antifungal agent.
Claim 11
Dependent Claim
18 words
The composition of claim 1 wherein the drug or diagnostic agent is a drug active against tumor cells.
Claim 12
Dependent Claim
30 words
The composition of claim 1 wherein the drug or diagnostic agent is a drug active in treating biological lesions which involve activated or diseased endothelium or subendothelial molecules or structures.
Claim 13
Dependent Claim
19 words
The composition of claim 1 wherein the carrier comprises one or more of macromolecules, microaggregates, microparticles, microspheres, and microemulsions.
Claim 14
Dependent Claim
19 words
The composition of claim 1 wherein the multivalent binding agent surface binds to laminin, collagen, fibronectin or fibronectin fragments.
References Cited (Backward Citations)
GB1516348A
Cited
GB2041517A
Cited
CA1168150A
Cited
EP0087786A1
Cited
WO1983003426A1
Cited
WO1984000294A1
Cited
EP0167825A2
Cited
GB2185397A
Cited
US4904479A
Cited
EP0240424A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-04-28 | 1995-10-28 | 1996-04-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-04-28 | 1999-10-28 | 2000-04-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-04-28 | 2003-10-28 | 2004-04-28 | $7700.00 | Window Closed / Lapsed |